Alexandre Delarue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandre Delarue has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ali Houeijeh
Institut CŒUR Poumon
2 shared publications - François Godart
Paediatric and Congenital Cardiology Department, Heart and Lung Institute, University Hospital of Lille , Lille 59000
2 shared publications - Jean Benoit Baudelet
Service de Cardiologie infantile et congénitale CHU de Lille Lille France
2 shared publications - Olivia Domanski
CHU Lille, Hôpital Cardiologique, Lille, France
2 shared publications - Anne Sophie Polge
Department of Echocardiography and Physiology, Institut Cœur Poumon, CHRU Lille, 59000 Lille, France
1 shared publication - Julien De Jonckheere
INSERM CIC-IT 807, University Hospital of Lille, Institut Hippocrate, 2 avenue Oscar Lambret 59037, France
1 shared publication
Latest Publications
- Open Access
- 9 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6410
Efficiency and Impact of Hypnoanalgesia for Cardiac Catheterisation in Paediatric Population
Hypnoanalgesia is a promising non-pharmacologic adjunct technique in paediatric interventions. Its safety, efficiency, and impacts on paediatric cardiac catheterisation (CC) are unknown. Methods: In a prospective study, patients aged p = 0.62). No complications were reported. Conclusion: Paediatric CC is feasible and safe under hypnoanalgesia, even in complicated cases. Hypnoanalgesia was efficient in managing pain and stress, and it ensures more reliable pressure measurements.
- 9 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6410
Open AccessEfficiency and Impact of Hypnoanalgesia for Cardiac Catheterisation in Paediatric Population
Hypnoanalgesia is a promising non-pharmacologic adjunct technique in paediatric interventions. Its safety, efficiency, and impacts on paediatric cardiac catheterisation (CC) are unknown. Methods: In a prospective study, patients aged p = 0.62). No complications were reported. Conclusion: Paediatric CC is feasible and safe under hypnoanalgesia, even in complicated cases. Hypnoanalgesia was efficient in managing pain and stress, and it ensures more reliable pressure measurements.
- Open Access
- 5 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6370
Transcatheter Closure of Perimembranous Ventricular Septal Defects Including Multifenestrated and Gerbode-Type Defects Using the Lifetech Konar Device
(1) Transcatheter closure of perimembranous ventricular septal defects (PmVSD) is becoming more attractive and effective with the development of new occluders. The aim of this study was to report a single-center experience in PmVSD closure using the Lifetech Konar-multifunctional occluder (MFO). (2) From March 2019 to October 2022, 43 consecutive patients were enrolled in the study. Among them, 13 had multifenestrated PmVSD including 5 Gerbode-type defects. (3) There were 23 males/20 females, and the median age was 17 years (range 2–68 years). Trivial aortic regurgitation was noticed in 19 patients. Implantation was successful in all patients under general anesthesia. A retrograde approach was used in 35 patients (81%). The retrograde approach was associated with a lower radiation dose (p = 0.042) and shorter fluoroscopy time (p = 0.002) compared to the antegrade approach. Full occlusion was observed immediately in 12 patients (28%) and in 33 patients (77%) at a median follow-up of 11 months. There were no complications such as embolization, complete atrioventricular block, device dislocation, new onset above grade I, or progression of tricuspid or aortic valve regurgitation. Seven of the thirteen patients with a multifenestrated defect had no residual shunt. The persistent shunts were all trivial intra-prosthetic leaks. (4) MFO is effective and safe for PmVSD closure including multifenestrated/Gerbode-type defects with no complication. However, a longer follow-up remains warranted to establish the safety of this technique.
- 5 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6370
Open AccessTranscatheter Closure of Perimembranous Ventricular Septal Defects Including Multifenestrated and Gerbode-Type Defects Using the Lifetech Konar Device
(1) Transcatheter closure of perimembranous ventricular septal defects (PmVSD) is becoming more attractive and effective with the development of new occluders. The aim of this study was to report a single-center experience in PmVSD closure using the Lifetech Konar-multifunctional occluder (MFO). (2) From March 2019 to October 2022, 43 consecutive patients were enrolled in the study. Among them, 13 had multifenestrated PmVSD including 5 Gerbode-type defects. (3) There were 23 males/20 females, and the median age was 17 years (range 2–68 years). Trivial aortic regurgitation was noticed in 19 patients. Implantation was successful in all patients under general anesthesia. A retrograde approach was used in 35 patients (81%). The retrograde approach was associated with a lower radiation dose (p = 0.042) and shorter fluoroscopy time (p = 0.002) compared to the antegrade approach. Full occlusion was observed immediately in 12 patients (28%) and in 33 patients (77%) at a median follow-up of 11 months. There were no complications such as embolization, complete atrioventricular block, device dislocation, new onset above grade I, or progression of tricuspid or aortic valve regurgitation. Seven of the thirteen patients with a multifenestrated defect had no residual shunt. The persistent shunts were all trivial intra-prosthetic leaks. (4) MFO is effective and safe for PmVSD closure including multifenestrated/Gerbode-type defects with no complication. However, a longer follow-up remains warranted to establish the safety of this technique.